TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · major macro event coming up
BRCHF

BrainChip Holdings Ltd

Technology · Semiconductors

0.089$ -6.3% vs. previous close Closing price · As of: Sep 30, 2026
🔔 Watch stock
Add to watchlist

Share this page

LinkedIn WhatsApp Email

Stock Watch

Stock Watch will tell you what changes at BrainChip Holdings Ltd.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 0.089 $ to 0.167 $ · Last price: 0.089 $ (As of: September 30, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 0.2$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 2,416m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 80.6%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. 0.2

Performance

Perf. 1M ?Price performance over the last month. -6.50%
Perf. 3M ?Price performance over the last 3 months. -16.70%
Perf. 6M ?Price performance over the last 6 months. -1.00%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). -12.28%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -40.1%
Perf. 1Y ?Price performance over the last 12 months. -34.07%
Perf. 3Y ?Price performance over the last 3 years. -28.80%
Perf. 5Y ?Price performance over the last 5 years. -70.63%
Perf. 10Y ?Price performance over the last 10 years. -66.91%
Perf. Since Inception ?Price performance since the first available trading day (05/13/2015) — with a complete history, that is since the IPO. -57.31%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 0.0971$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 0.0963$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 0.1091$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 39.7
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 63.9%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 77.5%

Calculated from the price history · as of 10/01/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. –
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 0.0
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 7.0
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. –
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. -14.5
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. –

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. 45.6%
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. -1,125.4%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. 0.0%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -81.0%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). -64.9%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 89.9%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.0
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. fortress balance sheet 32.33
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. –

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 196.40%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 374.15%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. 133.16%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. –

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. B (70 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Semiconductors

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
BrainChip Holdings Ltd BRCHF 0.2 – -14.5 45.6 -1,125.4 374.2 -34.1
NVIDIA Corporation NVDA 5,770.2 31.6 23.5 74.7 65.6 65.5 22.7
Broadcom Inc AVGO 1,670.9 55.8 33.9 75.5 49.0 23.9 7.3
Micron Technology Inc MU 1,383.6 22.5 17.8 72.6 80.4 48.9 537.6
Advanced Micro Devices Inc AMD 1,058.6 199.5 94.2 55.7 14.4 34.3 278.1
Intel Corporation INTC 604.1 – 182.0 38.9 6.9 -0.5 258.4
Arm Holdings plc ARM 309.4 292.7 304.3 97.5 7.6 22.8 104.7
Marvell Technology Group Ltd MRVL 255.1 87.4 49.9 52.2 14.5 42.1 214.9
Texas Instruments Incorporated TXN 254.9 43.1 26.3 58.3 37.8 13.1 56.4
Median of companies shown 604.1 55.8 33.9 58.3 14.5 34.3 104.7

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year $M

Revenue Operating income Net income

2017 · Revenue: 0 $M 2017 · Operating income: -18 $M 2017 · Net income: -18 $M 2018 · Revenue: 1 $M 2018 · Operating income: -22 $M 2018 · Net income: -23 $M 2019 · Revenue: 0 $M 2019 · Operating income: -16 $M 2019 · Net income: -16 $M 2020 · Revenue: 0 $M 2020 · Operating income: -15 $M 2020 · Net income: -35 $M 2021 · Revenue: 2 $M 2021 · Operating income: -20 $M 2021 · Net income: -21 $M 2022 · Revenue: 5 $M 2022 · Operating income: -22 $M 2022 · Net income: -22 $M 2023 · Revenue: 0 $M 2023 · Operating income: -29 $M 2023 · Net income: -29 $M 2024 · Revenue: 0 $M 2024 · Operating income: -23 $M 2024 · Net income: -24 $M 2025 · Revenue: 2 $M 2025 · Operating income: -20 $M 2025 · Net income: -20 $M
201720182019202020212022202320242025
Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2017 0 -18 -18 -0.02 -6 23 25
2018 1 -22 -23 -0.02 -7 13 14
2019 0 -16 -16 -0.01 -9 13 16
2020 0 -15 -35 -0.02 -10 23 31
2021 2 -20 -21 -0.01 -14 19 24
2022 5 -22 -22 -0.01 -14 24 29
2023 0 -29 -29 -0.02 – 17 20
2024 0 -23 -24 -0.01 – 20 23
2025 2 -20 -20 -0.01 – 31 34

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 – – 4 – 1
12/31/2027 – – 8 – 1

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

AI classification

AI Rating

Sells AI

BrainChip entwickelt und lizenziert mit dem neuromorphen Akida-Prozessor ein reines KI-Produkt; das einzige Geschäftssegment besteht aus lizenzierbaren Designs auf Basis künstlicher neuronaler Netze, und der gesamte Umsatz 2025 (1.887.155 US-$ aus Produktverkäufen und Entwicklungsdienstleistungen) stammt aus diesem KI-Geschäft.

View the full file — quotes, sources, reviewed filings
„The principal activity of the Group is the development of software and hardware accelerated solutions for advanced artificial intelligence (“AI”) and machine learning applications, with a primary focus on the development of its Akida™ (“Akida”) neuromorphic processor to provide a complete ultra-low power and fast AI Edge Network for vision, audio, olfactory and smart transducer applications."

Die Haupttätigkeit des Konzerns ist die Entwicklung software- und hardwarebeschleunigter Lösungen für fortgeschrittene Anwendungen der künstlichen Intelligenz („KI“) und des maschinellen Lernens, mit einem Schwerpunkt auf der Entwicklung seines neuromorphen Akida™-Prozessors, der ein vollständiges, äußerst stromsparendes und schnelles KI-Edge-Netzwerk für Anwendungen in den Bereichen Bild, Ton, Geruch und intelligente Messwandler bereitstellen soll.

Jahresbericht 2025 (ASX-Annual-Report, Directors’ Report, „Principal activities“) · 2026-02-26 · View SEC filing

„For management purposes, the Group is organised into one operating segment, being the technological development of designs that can be licensed to OEM (Original Equipment Manufacturer) Customers, End Users and System Integrators based on Artificial Neural Networks."

Für Steuerungszwecke ist der Konzern in einem einzigen Geschäftssegment organisiert: der technologischen Entwicklung von Designs auf Basis künstlicher neuronaler Netze, die an Erstausrüster (OEM), Endanwender und Systemintegratoren lizenziert werden können.

Jahresbericht 2025 (ASX-Annual-Report, Anhangangabe 11 „Operating segments“) · 2026-02-26 · View SEC filing

„During the quarter ending 30 June 2026, BrainChip continued to execute its strategy of commercialising ultra-low-power neuromorphic artificial intelligence technology through customer engagements, ecosystem expansion, reference platform introductions, strategic licensing agreements and volume production of the AKD1500 neuromorphic processor."

Im Quartal bis zum 30. Juni 2026 setzte BrainChip seine Strategie fort, äußerst stromsparende neuromorphe Technologie der künstlichen Intelligenz zu kommerzialisieren — über Kundenprojekte, den Ausbau des Ökosystems, die Einführung von Referenzplattformen, strategische Lizenzvereinbarungen und die Serienfertigung des neuromorphen Prozessors AKD1500.

Quartalsbericht und Quartals-Kassenbericht (Appendix 4C) zum 30.06.2026, Abschnitt „Commercialisation Strategy“ · 2026-07-27 · View SEC filing

Filings Reviewed: Jahresbericht 2025 (ASX-Annual-Report, geprüft von HLB Mann Judd) 2026-02-26 · Appendix 4E (vorläufiger Jahresabschluss 2025) 2026-02-26 · Quartalsbericht + Quartals-Kassenbericht (Appendix 4C) zum 30.06.2026 2026-07-27 · Quartals-Kassenbericht (Appendix 4C) zum 31.03.2026 2026-04-24 · ASX-Meldung „Expiration of LDA Put Option Agreement“ 2026-07-24 · ASX-Meldung Appendix 3G (nicht notierte Bezugsrechte) 2026-07-06

Rated on August 17, 2026 · How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

4 of 10 Weak growth
  • Revenue grows by more than 15% a year over three years -28.1%
  • More than 10% revenue growth is expected for the coming year 133.2%
  • Share count grows by less than 3% a year 8.9%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
  • Gross margin at 40% or higher and without meaningful erosion 14.1%
  • Goodwill from acquisitions does not grow faster than revenue 0.0%
  • Net debt below twice EBITDA 32 m net cash
  • Operating cash flow covers the profits of the last three years no data
  • Return on capital at 15% or higher, or up versus two years ago -63.1%
  • Insiders hold at least 10% or are net buyers 13.0%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

4/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% 23.5%
  • Exp. sales growth 3Y > 5% 103.1%
  • EBIT growth 10Y > 5% –
  • Exp. EBIT growth 3Y > 5% 103.1%
  • Net debt < 4x EBIT –
  • EBIT positive, 10Y straight 0
  • Max. EBIT decline < 50% –
  • Return on equity > 15% -66.7%
  • ROCE > 15% -63.1%
  • Expected return > 10% 86.7%

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

The company

About the Company

BrainChip Holdings Ltd develops software and hardware accelerated solutions for artificial intelligence and machine learning applications in North America, Asia Pacific, Europe, the Middle East, and Asia Pacific. The company primarily focuses on development of Akida Neuromorphic Processor to provide ultra-low power and AI Edge Network for vision, audio, olfactory, and smart transducer applications. It also offers Akida IP, a neural processor; MetaTF software development tools, which is used for creation, training, testing, and deployment of neutral network; Akida Cloud, a service that provides a pre-configured environment for system and chip designers; and Akida GenAI FPGA, a hardware development target to install and exercise Akida GenAI IP core configurations to execute neural models for validation and system integration for system and chip designers. In addition, the company provides hardware development tools comprising AKD1000 PCIe Development Board, a compact platform designed to accelerate Edge AI development; Akida M.2 AKD1000 Card which accelerates CNN-based neural network models; AKIDA 1 Edge AI Box, a compact system with the capability to execute diverse AI applications at the edge; Akida FPGA Platform, a hardware product for loading Akida IP configurations and neural models; and Akida AKD1000 System-on-Chip, a event domain neural processing devices. Further, it offers Akida Model Zoo comprising AkidaNet/Object Detection, AkidaNet/Object Classification/Recognition, AkidaNet/Regression, AkidaNet/Face Recognition, AkidaNet/Keyword Spotting, AkidaNet/Point Cloud Classification, AkidaNet/TENN Gesture Recognition Model, and AkidaNet/TENN Eye Tracking Model; and TENNs Models which includes AkidaNet/TENN Audio Denoising Model, AkidaNet/TENN Automatic Speech Recognition Model, and AkidaNet/ TENN Large Language Model. The company was formerly known as Aziana Limited. BrainChip Holdings Ltd is based in Sydney, Australia.

Employees
71
Headquarters
Sydney, NSW
Address
210 George Street, 2000 Sydney, Australia
Phone
61 2 9290 9606
ISIN
US10488Q1022
Stock Split
1077:1000 on 06/27/2019

Management

Management
Name Title Birth Year
Sean Hehir B.S., M.B.A. CEO, MD & Executive Director –
Peter Adrain J Van der Made M.Sc. Founder, Member of Scientific Advisory Board & Non-Executive Director –
Ken Scarince Chief Financial Officer –
Anil Shamrao Mankar Co-Founder & Advisor 1956
M. Anthony Lewis Chief Technology Officer –
Steven Brightfield Chief Marketing Officer –
James Shields Vice President of Sales & Business Development –
Jonathan Tapson Chief Development Officer –
Kim Larkin Company Secretary 1969

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?